2012

Providers and supporters of continuing medical education (CME) "have gotten the message" and are delivering content without…

In order to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease, Merck…

A recent study published in Critical Pathways in Cardiology analyzed the results of a continuing medical education (CME) program…

Over the past few years, there has been no shortage of legal cases brought by federal and state prosecutors against drug and…

Since the Drug Price Competition and Patent Term Restoration Act of 1984—commonly known as the Hatch-Waxman Act—generic drugs have…

Those of us in the continuing medical education (CME) community have seen a growing movement over the past several years to…

In 2010, the Department of Veterans Affairs ("VA") proposed a regulation that would impose limits on the promotion of drug and…

Earlier this month, the Food and Drug Administration (FDA) released a new Clinical Trials Guidance Document.  The guidance…

As we have covered numerous times on this blog, in 2009, the State of Massachusetts enacted the Massachusetts Pharmaceutical and…

The Europeans are now joining the chorus for principled relationships with industry.  The European Society of Cardiology…